Hyrimoz® (adalimumab-adaz) – New biosimilar strength approval
March 21, 2023 - Sandoz announced the FDA approval of Hyrimoz (adalimumab-adaz) citrate-free, high concentration (100 mg/mL) injection, biosimilar to AbbVie’s Humira® (adalimumab).
Download PDF
